Our lead candidate is Lasofoxifene
Sermonix Pharmaceuticals, founded in late 2014 by David Portman, MD, a leading clinical researcher and expert in women’s health, menopause and selective estrogen receptor modulators, is a privately held biotechnology company focused on the development and commercialization of female-specific oncology products.
Extensively studied, Sermonix is investigating Lasofoxifene for breast and ovarian cancer treatments. Demonstrated efficacy in reducing the incidence of ER+ breast cancer in women with osteoporosis.
SERMONIX PHARMACEUTICALS SIGNS EXCLUSIVE LICENSING AGREEMENT TO FURTHER EXPLORE LASOFOXIFENE FOR BREAST CANCER TREATMENT.